Olipudase Alfa
CAS 927883-84-9 1 FDA-DMF supplierBiologic
Overview
Olipudase Alfa is a recombinant human enzyme replacement therapy for the treatment of acid sphingomyelinase deficiency, which leads to Niemann-Pick disease types A and B. It works by replacing the deficient enzyme, thereby helping to reduce sphingomyelin accumulation in organs, particularly the liver and spleen.
Therapeutic areas
Lysosomal Storage DisordersNiemann-Pick Disease
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.